摘要
目的回顾性观察左西孟旦治疗扩张型心肌病（DCM）心衰患者生存质量情况,及超声心动图下心脏重构和心功能的变化情况。方法入选DCM且心功能Ⅲ~Ⅳ级（NYHA分级）的患者,随机分为左西孟旦治疗组和对照组,入院及随访时填写SF-36生存质量调查表并行超声心动图检查心脏结构和功能。结果用药组患者在治疗后1个月和3个月时的生存质量评分高于对照组。心脏彩超显示两组治疗后射血分数无明显改善,但用药组治疗后房室内径缩小。结论对DCM心衰患者应用左西孟旦可显著提高3个月内的生存质量,延缓6个月内心脏重构进程,但无法明显逆转心脏重构及改善心功能。
Objective We retrospectively observed the quality of life and the changes of cardiac remodeling and cardiac function in patients with dilated cardiomyopathy（DCM） and chronic heart failure after levosimendan treatment. Methods Patients with DCM within NYHA Ⅲ ~ Ⅳ were selected. They received SF-36 test and echocardiography on admission and in a follow-up visit. Results Levosimendan treatment group had the higher level of quality of life on1 month and 3 months than admission. Echocardiography showed there was no difference of ejection fraction between levosimendan treatment group and control group. However, the size of left atria and ventricle were reduced after levosimendan treatment. Conclusions Levosimendan significantly improve the quality of life of patients with DCM within 3 months, and delays the cardiac remodeling process in 6 months. Levosimendan could not significantly reverse the cardiac remodeling and improve heart function.
出处
《中国分子心脏病学杂志》
CAS
2015年第5期1441-1443,共3页
Molecular Cardiology of China
